Oral Semaglutide (Rybelsus): How It Works

Oral Peptide Delivery

~1% oral bioavailability

Oral semaglutide achieves approximately 1% bioavailability through SNAC-mediated gastric absorption, enough to produce therapeutic GLP-1 receptor activation from a daily pill.

Aroda et al., Drug Discovery Today, 2022

Aroda et al., Drug Discovery Today, 2022

View as image

Peptides are not supposed to survive the stomach. Gastric acid (pH 1-2) denatures protein structures, and pepsin cleaves peptide bonds within minutes. For decades, this biological reality meant that peptide drugs required injection. Then in September 2019, the FDA approved Rybelsus (oral semaglutide), the first oral GLP-1 receptor agonist, proving that a peptide could be taken as a daily pill and still produce clinically meaningful effects on blood sugar and body weight.^[1] For the broader context of why oral peptide delivery is so difficult, see The Race for Oral Tirzepatide.

The trick is SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), a small-molecule absorption enhancer co-formulated with semaglutide in each tablet. SNAC solves three problems simultaneously: it buffers local pH to protect semaglutide from acid degradation, it promotes monomerization of the peptide for better absorption, and it transiently increases gastric epithelial permeability to allow semaglutide to cross into the bloodstream.^[2] The result: approximately 1% oral bioavailability, a number that sounds low until you consider that it produces the same GLP-1 receptor activation as subcutaneous injection.

The SNAC Solution: Three Mechanisms in One Tablet

Each Rybelsus tablet contains semaglutide (3, 7, or 14 mg) co-formulated with 300 mg of SNAC. When the tablet reaches the stomach, SNAC dissolves and creates a localized microenvironment around the semaglutide molecules that enables absorption through the gastric wall.

Solis-Herrera et al. (2024) published the most comprehensive review of SNAC's mechanism in Clinical Diabetes, identifying three distinct actions:^[3]

1. Local pH buffering. SNAC raises the pH in the immediate vicinity of the dissolving tablet, creating a neutral microenvironment within the acidic stomach. This pH shift reduces the conversion of pepsinogen to active pepsin, protecting semaglutide from enzymatic degradation during the critical absorption window.

2. Monomerization. GLP-1 receptor agonists like semaglutide naturally self-associate into oligomers (clusters of multiple molecules) in solution. Only monomeric semaglutide can cross the gastric epithelium efficiently. SNAC changes the polarity of the local solution, weakening the hydrophobic interactions that drive oligomerization and promoting the monomeric form.

3. Transient membrane permeability. SNAC interacts with and fluidizes the lipid membranes of gastric epithelial cells, increasing transcellular permeability. This effect is confined to the immediate area around the tablet and reverses within approximately 30 minutes. SNAC does not affect tight junctions between cells (paracellular transport), which distinguishes it from other permeation enhancers that may cause more lasting epithelial disruption.

Preclinical studies in dogs using pyloric ligation confirmed that the stomach is the predominant absorption site. Semaglutide that passes into the intestine without being absorbed is destroyed by pancreatic enzymes.^[2]

Kommineni et al. (2023) reviewed SNAC's broader applications and noted that this absorption enhancer was originally developed in the 1990s for oral heparin delivery. Its repurposing for semaglutide represents one of the most commercially successful applications of pharmaceutical permeation enhancement technology.^[4]

For a dedicated analysis of the SNAC technology itself, see The SNAC Technology Behind Oral Peptide Absorption. The broader challenge of getting peptides through the GI tract is covered in Why Oral Peptide Delivery Is One of Pharma's Hardest Problems.

Pharmacokinetics: What 1% Bioavailability Actually Means

Overgaard et al. (2021) published a comprehensive pharmacokinetic analysis of oral semaglutide from clinical pharmacology studies. Key findings:^[5]

• Absolute oral bioavailability is approximately 0.4-1% (varying by individual and dosing conditions)
• Peak plasma concentration occurs 1-2 hours after dosing
• The half-life of semaglutide itself is approximately 1 week (identical to injectable semaglutide), so daily oral dosing produces steady-state accumulation
• Food substantially reduces absorption: taking Rybelsus with food decreased bioavailability by approximately 40% compared to fasting conditions

The dosing instructions reflect these pharmacokinetics: patients must take Rybelsus on an empty stomach with no more than 4 oz (120 mL) of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. These restrictions exist because food in the stomach dilutes the SNAC concentration, reduces gastric pH buffering, and physically separates semaglutide from the gastric wall.

The 1% bioavailability means that a 14 mg oral dose delivers roughly the same semaglutide exposure as a 1 mg weekly subcutaneous injection, distributed across 7 daily doses. The pharmacologic target (GLP-1 receptor activation at therapeutic levels) is the same; the delivery route produces identical receptor-level effects once the peptide reaches the bloodstream. For a direct comparison of oral and injectable formulations, see Oral vs Injectable Semaglutide.

Clinical Evidence: PIONEER, OASIS, and SOUL

The PIONEER Program (Type 2 Diabetes)

Oral semaglutide was approved based on the PIONEER clinical trial program, a series of 10 Phase 3 trials in patients with type 2 diabetes. Lewis et al. (2022) reviewed the development pathway and trial results that led to FDA approval:^[1]

• PIONEER 1: Oral semaglutide 14 mg reduced HbA1c by 1.5% from baseline versus 0.02% for placebo
• PIONEER 4: Oral semaglutide 14 mg was non-inferior to subcutaneous liraglutide 1.8 mg for HbA1c reduction and superior for weight loss
• PIONEER 7: Flexible-dose oral semaglutide was superior to sitagliptin for HbA1c reduction

Across the program, oral semaglutide consistently reduced HbA1c by 1.0-1.5% and body weight by 3-5 kg at the 14 mg dose, with a safety profile similar to other GLP-1 receptor agonists (primarily gastrointestinal side effects).

OASIS 1 (Obesity Without Diabetes)

Knop et al. (2023) published the OASIS 1 trial in The Lancet, testing a higher oral semaglutide dose (50 mg) specifically for weight management in adults with overweight or obesity but without diabetes. Results at 68 weeks:^[6]

• Mean weight loss: 15.1% with oral semaglutide 50 mg versus 2.4% with placebo
• 85% of participants achieved at least 5% weight loss (vs. 26% placebo)
• 69% achieved at least 10% weight loss (vs. 12% placebo)
• 54% achieved at least 15% weight loss (vs. 6% placebo)

These results approach the efficacy of subcutaneous semaglutide 2.4 mg (Wegovy), which produced 14.9% weight loss in the STEP 1 trial. Wharton et al. (2025) subsequently reported results for the 25 mg oral dose in adults with overweight or obesity, demonstrating that even this lower dose produced clinically significant weight reduction.^[7]

For context on how these weight loss results compare across the GLP-1 class, see How Much Weight Can You Lose on Semaglutide? and Liraglutide vs Semaglutide.

The SOUL Trial (Cardiovascular Outcomes)

The SOUL trial, published by McGuire et al. in the New England Journal of Medicine in 2025, was the first cardiovascular outcomes trial dedicated to oral semaglutide. In 9,650 patients with type 2 diabetes at high cardiovascular risk:^[8]

• Oral semaglutide 14 mg reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 14% versus placebo (HR 0.86, 95% CI 0.77-0.96)
• The cardiovascular benefit was consistent across subgroups including those with and without established cardiovascular disease
• This confirmed that oral semaglutide provides the same cardiovascular protection previously demonstrated for injectable GLP-1 receptor agonists

Appetite and Energy Intake Effects

Gabe et al. (2024) studied the direct effects of oral semaglutide on appetite, energy intake, and gastric emptying in a controlled clinical pharmacology study:^[9]

Oral semaglutide reduced ad libitum energy intake, decreased appetite ratings, and slowed gastric emptying compared to placebo. The appetite suppression pattern was consistent with central GLP-1 receptor activation in hypothalamic appetite centers rather than a purely local gastrointestinal effect.

Selvarajan et al. (2023) reviewed oral semaglutide's clinical pharmacology for type 2 diabetes management, noting that the weight loss effects are mediated through reduced caloric intake (approximately 24% reduction) rather than increased energy expenditure.^[10] For how semaglutide affects body composition specifically, see Does Semaglutide Change Your Body Composition?.

The Dosing Challenge: Why Instructions Matter

Oral semaglutide's strict dosing requirements are its primary limitation compared to injectable formulations. The fasting requirement, the water restriction, and the 30-minute waiting period before food or other medications create adherence challenges that injectable once-weekly dosing avoids.

Real-world data from the PIONEER REAL studies (conducted across Japan, UK, Sweden, Spain, Italy, and other countries) consistently show that a substantial minority of patients do not follow dosing instructions precisely. A 2024 study by Horii et al. found that adherence to the fasting requirement was the strongest predictor of oral semaglutide's clinical effectiveness: patients who consistently dosed correctly achieved HbA1c reductions comparable to clinical trial results, while those with inconsistent compliance showed attenuated responses.

Shapira-Furman et al. (2024) explored modifications to the SNAC co-formulation (phenolate salts) that could potentially improve bioavailability and reduce the sensitivity of absorption to food timing, though these remain in preclinical development.^[11]

What Comes Next: Orforglipron and Beyond

The next generation of oral GLP-1 drugs may not need SNAC at all. Orforglipron, developed by Eli Lilly, is a non-peptide, small-molecule oral GLP-1 receptor agonist. Because it is not a peptide, it has natural oral bioavailability and does not require absorption enhancement, fasting conditions, or water restrictions.

Wharton et al. (2023) published the Phase 2 trial of orforglipron in adults with obesity in the New England Journal of Medicine. At the highest dose (45 mg daily), orforglipron produced 14.7% body weight reduction at 36 weeks, comparable to injectable semaglutide.^[12] Phase 3 results are expected in 2026.

If orforglipron succeeds, it will represent a fundamentally different approach to the oral peptide problem: instead of engineering a peptide to survive the gut, engineer a non-peptide molecule that activates the same receptor. This could make SNAC-based approaches obsolete for GLP-1 therapy specifically, though SNAC remains relevant for other peptide drugs that lack non-peptide alternatives. For how tirzepatide is approaching oral formulation, see The Race for Oral Tirzepatide.

Side Effects

Oral semaglutide shares the GLP-1 class side effect profile. The most common adverse effects are gastrointestinal: nausea (affecting 15-20% of patients at the 14 mg dose), diarrhea, vomiting, and decreased appetite. These effects are typically dose-dependent and diminish over weeks as the dose is gradually escalated.

The SOUL trial's safety data confirmed no new safety signals over a median 4.5-year follow-up period, including no increased risk of pancreatitis, thyroid cancer, or severe hypoglycemia when used without sulfonylureas.^[8]

A unique consideration for oral semaglutide: SNAC is absorbed along with semaglutide but is rapidly metabolized. A 2026 study by Ariaee et al. found that SNAC's salcaprozate sodium component may cause gut microbiota perturbation in some patients, though the clinical significance of this finding is uncertain.

For a full review of GLP-1 drug safety, see GLP-1 Side Effects: What to Expect and Every GLP-1 Receptor Agonist Compared.

The Bottom Line

Oral semaglutide proved that a peptide drug can survive the stomach and produce therapeutic effects from a daily pill. The SNAC absorption enhancer enables approximately 1% oral bioavailability through local pH buffering, peptide monomerization, and transient membrane permeability enhancement. Clinical trials demonstrate efficacy comparable to injectable GLP-1 agonists for both diabetes (PIONEER program) and obesity (OASIS 1, 15.1% weight loss at 50 mg), with confirmed cardiovascular benefit in the SOUL trial. Strict dosing requirements limit real-world effectiveness for some patients. Non-peptide alternatives like orforglipron may eventually bypass the oral peptide delivery challenge entirely.

Frequently Asked Questions

How does oral semaglutide work?

Oral semaglutide (Rybelsus) is co-formulated with SNAC, an absorption enhancer that protects the peptide from stomach acid, promotes its monomeric form for better absorption, and transiently increases gastric membrane permeability. The tablet is absorbed through the stomach wall with approximately 1% bioavailability. Once in the bloodstream, semaglutide activates GLP-1 receptors in the pancreas (increasing insulin secretion) and brain (reducing appetite), identical to injectable semaglutide.

Why do you have to take Rybelsus on an empty stomach?

Food in the stomach dilutes the SNAC concentration around the tablet, reduces the local pH buffering that protects semaglutide from acid degradation, and physically separates the peptide from the gastric wall where absorption occurs. Studies show that taking Rybelsus with food decreases bioavailability by approximately 40% (Overgaard et al., 2021). The instructions specify no more than 4 oz of plain water, followed by a 30-minute fast before eating or other medications.

Is oral semaglutide as effective as the injection?

For blood sugar control, oral semaglutide 14 mg produces HbA1c reductions of 1.0-1.5%, comparable to subcutaneous liraglutide 1.8 mg (PIONEER 4 trial). For weight loss, the higher 50 mg oral dose produced 15.1% mean weight loss in the OASIS 1 trial, approaching injectable semaglutide 2.4 mg (Wegovy), which produced 14.9% in STEP 1. Cardiovascular protection was confirmed by the SOUL trial (14% reduction in MACE, McGuire et al., 2025).

What is SNAC in semaglutide tablets?

SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) is a small-molecule absorption enhancer that makes oral peptide delivery possible. Each Rybelsus tablet contains 300 mg of SNAC alongside the semaglutide. SNAC raises local stomach pH (protecting against pepsin), breaks apart semaglutide clusters into single molecules (monomerization), and temporarily increases stomach lining permeability for absorption. These effects reverse within 30 minutes and do not affect other co-administered medications.

What are the side effects of oral semaglutide?

The most common side effects are gastrointestinal: nausea (15-20% at 14 mg dose), diarrhea, vomiting, and decreased appetite. These are typically dose-dependent and improve over weeks with gradual dose escalation. The SOUL trial confirmed no increased risk of pancreatitis, thyroid cancer, or severe hypoglycemia over a median 4.5-year follow-up (McGuire et al., 2025). The side effect profile is consistent with the GLP-1 receptor agonist class as a whole.

Will there be a pill form of Wegovy?

Novo Nordisk has studied oral semaglutide at higher doses (25 mg and 50 mg) specifically for weight management. OASIS 1 showed the 50 mg dose produced 15.1% weight loss at 68 weeks (Knop et al., 2023). Wharton et al. (2025) reported results for the 25 mg dose. These higher-dose oral formulations use the same SNAC technology as Rybelsus. Regulatory submissions for weight management indications are in progress. A competing non-peptide oral GLP-1 agonist, orforglipron, is also in Phase 3 trials.